MicroRNA-183 suppresses the vitality, invasion and migration of human osteosarcoma cells by targeting metastasis-associated protein 1
Authors: Yan Zhang
Xuefeng Zhao
Xiaoya Sun
Yadong Wang
Yuebai Li
Yisheng Wang
Xinjie Li
Yan Xu
Shanfeng Zhang
Journal: Experimental and Therapeutic Medicine (2018)
Discipline: CLINICAL MEDICINE
Keywords: apoptosis; invasion; metastasis; metastasis-associated protein 1; microRNA-183
Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China., Department of Orthopedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

Abstract:  The aim of the present study was to investigate the effects of microRNA (miR)-183 on vitality, invasion, metastasis and apoptosis in osteosarcoma (OS) cells, mediated by its binding to metastasis-associated protein 1 (MTA1). A dual luciferase reporter assay was performed to determine whether MTA1 was a direct target of miR-183. Cell Counting Kit-8, Transwell, scratch-wound healing, fluorescence-activated cell sorting andterminal deoxynucleotidyl transferase dUTP nick end labeling assays were also performed to investigate the effects of miR-183 expression on the proliferation, invasion, migration and apoptosis of MG63 cells. It was demonstrated that that MTA1 expression levels were significantly higher in OS tissues and MG63 cells compared with corresponding adjacent noncancerous tissues and normal cells, respectively, while miR-183 expression levels were significantly lower (both P&lt;0.05). Furthermore, miR-183 overexpression downregulated MTA1 levels and inhibited cell proliferation (P&lt;0.05), migration (P&lt;0.05) and invasion (P&lt;0.01), as well as promoting apoptosis (P&lt;0.01) by binding to the 3'-untranslated region of MTA1. These results indicate that miR-183 inhibits the vitality, invasion, migration and apoptosis of the OS cell line MG63 by targeting MTA1. These findings may contribute to the development of novel clinical therapeutic approaches for the treatment of OS. 

Retracted: No

PubPeer comments:
 Figure 2C appears to have two images which overlap. *** ![file] *** ![file] , 
 Figure 4B (below bottom) in DOI: 10.3892 ol.2018.8239, also posted here: https: pubpeer.com publications 212BA1D23305C0BE5CA1D666353CA7 appears to share images from Figure 2C (below top) in this paper. They are described differently in the 2 papers. Could the authors explain? *** ![file] , 
 ![file] The negative control 48-hr panel has also appeared as  Blank (24 hours) in Fig 3B of [Zhao et al (2019)] . Among other problems. , 
 Please also compare the scratch-healing assay images (3E) from this paper *[left]* with *[right]* those from 3A of Zhao et al. ![file] I ran out of colors but you get the idea. The recycling is admirable in its parsimony. , 
 Corrigendum, [4 November 2021] . The appearance of the images in [Zhou et al (2019)] (with different labels) goes unmentioned.  Subsequently to the publication of the above article, an interested reader drew to the authorsu2019 attention that, on p. 5061, certain of the data panels featured in Fig. 2C (showing the results of Transwell assay experiments) and Fig. 2E (showing the results of scratchu2011wound healing assay experiments) featured some overlapping data panels, such that the data, which were intended to represent experiments performed under different experimental conditions, may have been derived from the same original source. The authors have reu2011examined their raw data and identified the data that should have been included in these two figure parts. The corrected version of Fig. 2 is shown below, now including replacement data for Fig 2C and E. Note that these errors did not have a major impact on either the overall results or on the conclusions reported in this study. The authors regret that these data were mistakenly and inadvertently incorporated into Fig. 2, and apologize to the readership for any inconvenience caused. ![file] ,